Kedrion-Kamada, Anti-COVID IG development update

Kedrion Biopharma and Kamada are forging ahead with the development of a new Anti-COVID Immunoglobulin therapy derived from the plasma of convalescent patients.

Watch today’s interview by Kamada’s CEO Amir London on LeFontiTV to learn more about the status of the project.